Free access to Elaprase
Tuesday, 02 September, 2008
The Hunter syndrome drug Elaprase, marketed by Genzyme Australasia, will be funded by the federal government under its life saving drugs program.
Hunter syndrome, or Mucopolysaccharidosis II, is a rare inherited enzyme disorder is caused by a deficiency in the iduronate-2-sulfatase enzyme, which is necessary for recycling certain complex carbohydrates.
Symptoms can include joint stiffness, breathing difficulties, heart problems, enlargement of the spleen an liver and skeletal deformities.
Elaprase replaces the missing enzyme needed to break down these complex carbohydrates.
Genzyme will continue providing free access to the treatment to two Hunter syndrome patients until it becomes government-funded on December 1.
Elevated blood protein levels predict mortality
Proteins that play key roles in the development of diseases such as cancer and inflammation may...
The microbiome helps to fight melanoma
Molecules produced by gut bacteria upon digestion of dietary fibre can improve the function of...
Heart implant brings hope to refractory angina patients
The coronary sinus reducer is understood to redistribute blood flow within the wall of the heart,...
